NeuroPace, Inc. (NASDAQ:NPCE) Receives Average Rating of "Moderate Buy" from Brokerages

Shares of NeuroPace, Inc. (NASDAQ:NPCE - Get Free Report) have earned an average recommendation of "Moderate Buy" from the six research firms that are covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $15.00.

Several equities analysts recently weighed in on NPCE shares. JPMorgan Chase & Co. raised their target price on shares of NeuroPace from $9.00 to $14.00 and gave the company an "overweight" rating in a research note on Tuesday, December 17th. Wells Fargo & Company reduced their target price on NeuroPace from $15.00 to $13.00 and set an "overweight" rating for the company in a research note on Wednesday, November 13th.

NeuroPace Stock Down 2.2 %

NASDAQ:NPCE traded down $0.27 during trading hours on Tuesday, reaching $11.84. 79,587 shares of the stock were exchanged, compared to its average volume of 104,186. The firm has a 50 day moving average of $10.56 and a 200 day moving average of $8.31. The company has a debt-to-equity ratio of 6.03, a current ratio of 5.59 and a quick ratio of 4.77. The stock has a market cap of $353.40 million, a PE ratio of -11.84 and a beta of 2.02. NeuroPace has a twelve month low of $5.45 and a twelve month high of $18.15.

NeuroPace (NASDAQ:NPCE - Get Free Report) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.19) EPS for the quarter, topping analysts' consensus estimates of ($0.26) by $0.07. The company had revenue of $21.06 million during the quarter, compared to the consensus estimate of $19.33 million. NeuroPace had a negative net margin of 36.74% and a negative return on equity of 205.41%. During the same period in the prior year, the business posted ($0.28) EPS. On average, equities analysts expect that NeuroPace will post -1 earnings per share for the current year.

Insider Activity at NeuroPace

In other NeuroPace news, major shareholder Ltd. Kck sold 4,878 shares of the stock in a transaction that occurred on Friday, October 18th. The shares were sold at an average price of $6.29, for a total transaction of $30,682.62. Following the transaction, the insider now owns 5,502,785 shares in the company, valued at $34,612,517.65. This represents a 0.09 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders sold 239,636 shares of company stock worth $1,320,344 in the last ninety days. 22.20% of the stock is owned by company insiders.

Hedge Funds Weigh In On NeuroPace

Hedge funds and other institutional investors have recently made changes to their positions in the company. JPMorgan Chase & Co. lifted its holdings in shares of NeuroPace by 106.3% in the third quarter. JPMorgan Chase & Co. now owns 11,997 shares of the company's stock worth $84,000 after acquiring an additional 6,181 shares during the last quarter. Rhumbline Advisers bought a new position in NeuroPace in the 2nd quarter valued at approximately $111,000. Financial Advocates Investment Management boosted its position in NeuroPace by 20.0% in the third quarter. Financial Advocates Investment Management now owns 18,000 shares of the company's stock valued at $125,000 after buying an additional 3,000 shares in the last quarter. Barclays PLC grew its stake in shares of NeuroPace by 346.0% during the third quarter. Barclays PLC now owns 20,633 shares of the company's stock worth $144,000 after buying an additional 16,007 shares during the last quarter. Finally, XTX Topco Ltd lifted its stake in shares of NeuroPace by 56.1% in the 2nd quarter. XTX Topco Ltd now owns 24,055 shares of the company's stock valued at $182,000 after acquiring an additional 8,643 shares during the last quarter. 78.83% of the stock is currently owned by institutional investors and hedge funds.

About NeuroPace

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.